```
 (FILE 'HOME' ENTERED AT 16:48:25 ON 22 DEC 2002)

     FILE 'REGISTRY' ENTERED AT 16:48:34 ON 22 DEC 2002
                E "3'-DEOXYCYTIDINE"/CN 25
L1            1 S E3
                E "3'-DEOXYURIDINE"/CN 25
L2            1 S E3
                E "3'-DEOXYURIDINE"/CN 25
                E "3'-FLUORO-3'-DEOXYURIDINE"/CN 25
L3            1 S E1

     FILE 'CAPLUS, MEDLINE, USPATFULL' ENTERED AT 16:53:35 ON 22 DEC 2002
L4          319 F L3
L5          319 S L3
L6           40 S L5 AND HEPATITIS
L7            4 S L6 AND HEPATITIS C
L8            1 S L7 AND (INTERFERON OR RIBARIRIN OR AMANTADINE OR RIMANTADINE

=>
```

FILE 'CAPLUS' ENTERED AT 16:04:28 ON 22 DEC 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'MEDLINE' ENTERED AT 16:04:28 ON 22 DEC 2002

FILE 'USPATFULL' ENTERED AT 16:04:28 ON 22 DEC 2002

=> s l2
L3 80 L2

=> s l2 and hepatitis
L4 9 L2 AND HEPATITIS

=> d l4 1-9 bib abs hitstr

=> d l4 1-9 bib abs hitstr

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2002 ACS
AN 2002:555629 CAPLUS
DN 137:125359
TI Preparation of nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
IN Carroll, Steven S.; Lafemina, Robert L.; Hall, Dawn L.; Himmelberger, Amy L.; Kuo, Lawrence C.; Maccoss, Malcolm; Olsen, David B.; Rutkowski, Carrie A.; Tomassini, Joanne E.; An, Haoyun; Bhat, Balkrishen; Bhat, Neelima; Cook, Phillip Dan; Eldrup, Anne B.; Guinosso, Charles J.; Prhavc, Marija; Prakash, Thazha P.
PA Merck & Co., Inc., USA; Isis Pharmaceuticals, Inc.
SO PCT Int. Appl., 235 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002057425	A2	20020725	WO 2002-US1531	20020118
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002147160	A1	20021010	US 2002-52318	20020118
PRAI	US 2001-263313P	P	20010122		
	US 2001-282069P	P	20010406		
	US 2001-299320P	P	20010619		
	US 2001-344528P	P	20011025		

OS MARPAT 137:125359
GI



I

AB The present invention provides the prepn. of nucleoside compds. I, wherein B is nucleobase, Y is H, alkylcarbonyl, phosphate; R1 is H, alkenyl, alkynyl, alkyl; R2 and R3 are independently H, OH, halogen, alkyl, alkoxy, alkenyloxy, alkylthio, alkylcarbonyloxy, aryloxycrbonyl, azido, amino, alkylamino; R1 and R2 together with the carbon atom to which they are attached form a 3- to 6-membered heterocycle; R4 is H, OH, SH, NH2, alkylamino, cycloalkylamino, halogen, alkyl, alkoxy, CF3; R5 and R6 are independently H, hydroxymethyl, Me, fluoromethyl; and certain derivs. thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compds. are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of **hepatitis** C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of **hepatitis** C infection. The invention also describes pharmaceutical compns. contg. such nucleoside compds. alone or

in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compds. of the present invention. Thus, 4-amino-1-(2-C-methyl-.beta.-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine was prepd. as inhibitors of RNA-dependent RNA viral polymerase. Representative compds. tested in the HCV NS5B polymerase assay exhibited IC's less than 100 .mu.M. The compds. of the present invention were also evaluated for their ability to affect the replication of **Hepatitis** C Virus RNA in cultured hepatoma (HuH-7) cells contg. a sub-genomic HCV Replicon.

IT **123402-24-4P 123402-25-5P**
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)

RN 123402-24-4 CAPLUS
CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123402-25-5 CAPLUS
CN Cytidine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2002 ACS
AN 2002:504634 CAPLUS
DN 137:57536
TI Remedies for **hepatitis** C
IN Morioka, Masahiko; Ubasawa, Masaru; Arai, Masaaki
PA Mitsubishi Pharma Corporation, Japan
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002051425	A1	20020704	WO 2001-JP11365	20011225

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI JP 2000-394620 A 20001226
JP 2001-23542 A 20010131
JP 2001-105585 A 20010404

OS MARPAT 137:57536

AB Excellent remedies for **hepatitis** C which contain as the active ingredients a 3'-deoxy-3'-fluorouridine deriv. and a 1-(3'-deoxy-3'-fluoro-.beta.-L-ribofuranosyl)uracil deriv. and show little side effects.

IT **57944-13-5DP**, 3'-Deoxy-3'-fluorouridine, derivs.
112668-56-1P 123402-24-4P 125217-37-0P
439579-20-1P 439579-21-2P 439579-22-3P
439579-24-5P 439579-25-6P 439579-26-7P
439579-28-9P 439579-32-5P 439579-34-7P
439579-36-9P 439579-37-0P 439579-38-1P
439579-40-5P 439579-41-6P 439579-42-7P
439579-43-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(deoxy-3'-fluorouridine deriv. and a 1-(3'-deoxy-3'-fluoro--L-ribofuranosyl)uracil deriv. as remedies for **hepatitis** C)

RN 57944-13-5 CAPLUS
CN Uridine, 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 112668-56-1 CAPLUS
CN Uridine, 3'-deoxy-3',5-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123402-24-4 CAPLUS
CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 125217-37-0 CAPLUS
CN Uridine, 3'-deoxy-3'-fluoro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-20-1 CAPLUS
CN Uridine, 5-cyano-3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 439579-21-2 CAPLUS
CN Uridine, 3'-deoxy-3'-fluoro-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-22-3 CAPLUS
CN Uridine, 5-bromo-3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-24-5 CAPLUS
CN Uridine, 3'-deoxy-3'-fluoro-2-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-25-6 CAPLUS
CN Uridine, 3'-deoxy-3'-fluoro-4-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-26-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-.beta.-L-ribofuranosyl)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-28-9 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-.beta.-L-ribofuranosyl)-5-
fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-32-5 CAPLUS
CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3',5-difluoro- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 439579-34-7 CAPLUS
CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-36-9 CAPLUS
CN Uridine 5'-(tetrahydrogen triphosphate), 5-cyano-3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-37-0 CAPLUS
CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-38-1 CAPLUS
CN Uridine 5'-(tetrahydrogen triphosphate), 5-bromo-3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-40-5 CAPLUS
CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro-2-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-41-6 CAPLUS
CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro-4-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 439579-42-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-deoxy-3-fluoro-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-.beta.-L-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-43-8 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-deoxy-3-fluoro-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-.beta.-L-ribofuranosyl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2002 ACS
AN 2002:314958 CAPLUS
DN 136:340939
TI Preparation of modified nucleosides for treatment of viral infections and abnormal cellular proliferation
IN Stuyver, Lieven; Watanabe, Kyoichi A.
PA Pharmasset Limited, USA
SO PCT Int. Appl., 230 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002032920	A2	20020425	WO 2001-US46113	20011018
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002028749	A5	20020429	AU 2002-28749	20011018
PRAI	US 2000-241488P	P	20001018		
	US 2001-282156P	P	20010406		
	WO 2001-US46113	W	20011018		

GI



I

AB Modified nucleosides, e.g. I, wherein D is hydrogen, alkyl, acyl, monophosphate, diphosphate, triphosphate, monophosphate ester, diphosphate ester, triphosphate ester, phospholipid or amino acid; X is H, halogen, NH2, substituted amine, oxime, OH, alkoxy, SH, thioalkyl; Y is O, S, Se; R and R1 are independently H, alkyl, alkenyl, alkynyl, aryl, alkylaryl, halogen, NH2, substituted amine, oxime, hydrazine, OH, alkoxy, SH, thioalkyl, NO2, NO, CH2OH, CH2OH, ester, CONH2, amide, CN; R2 and R3 are independently H, halogen, OH, SH, OMe, SMe, NH2, NHMe, CH:CH2, CN, CH2NH2, CH2OH, CO2H; were prepd. for treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and esp. humans. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction ("TR-PCR"). Addnl., the invention discloses probe mols. that can fluoresce proportionally to the amt. of virus present in a sample. Thus, (1'R,2'S,3'R,4'R)-1-[2,3-dihydroxy-4-(hydroxymethyl)cyclopentan-1-yl]-5-fluorocytosine was prepd. and tested in vitro as antiviral and antitumor agent.

IT **60786-48-3P 415704-55-1P**
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of modified nucleosides for treatment of viral infections and abnormal cellular proliferation)

RN 60786-48-3 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-(3-azido-3-deoxy-.beta.-D-arabinofuranosyl)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 415704-55-1 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-(3-azido-3-deoxy-.beta.-L-arabinofuranosyl)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2002 ACS
AN 2002:171918 CAPLUS
DN 136:217007
TI Preparation of antiviral nucleoside derivatives as inhibitors of subgenomic **hepatitis** C virus RNA replication
IN Devos, Rene; Dymock, Brian William; Hobbs, Christopher John; Jiang, Wen-rong; Martin, Joseph Armstrong; Merrett, John Herbert; Najera, Isabel; Shimma, Nobuo; Tsukuda, Takuo
PA F. Hoffmann-La Roche Ag, Switz.
SO PCT Int. Appl., 225 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002018404	A2	20020307	WO 2001-EP9633	20010821
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001095497	A5	20020313	AU 2001-95497	20010821
PRAI	GB 2000-21285	A	20000830		
	GB 2000-26611	A	20001031		
	WO 2001-EP9633	W	20010821		

OS MARPAT 136:217007

GI



I



II

AB Nucleosides I , wherein R1 is hydrogen, hydroxy, alkyl, hydroxyalkyl, alkoxy, halogen, cyano, isocyano or azido; R2 is hydrogen, hydroxy, alkoxy, chlorine, bromine or iodine; R3 is hydrogen; or R2 and R3 together represent =CH2; or R2 and R3 represent fluorine; X is O, S or CH2; B is a substituted purine base, were prepd. as inhibitors of subgenomic **hepatitis** C virus (HCV) RNA replication. Thus, nucleoside II was prepd. and tested for the inhibition of HCV RNA replication (EC50 = 0.6 .mu.M).

IT **26563-01-9P 125217-37-0P 129885-95-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of antiviral nucleoside derivs. as inhibitors of subgenomic **hepatitis** C virus RNA replication)

RN 26563-01-9 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-(3-deoxy-3-fluoro-.beta.-D-xylofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 125217-37-0 CAPLUS
CN Uridine, 3'-deoxy-3'-fluoro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129885-95-6 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-.beta.-D-xylofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2002 ACS
AN 2001:617773 CAPLUS
DN 135:175346
TI Method for the treatment or prevention of flavivirus infections using nucleoside analogues
IN Ismaili, Hicham Moulay Alaoui; Cheng, Yun-Xing; Lavallee, Jean-Francois; Siddiqui, Arshad; Storer, Richard
PA Biochem Pharma Inc., Can.
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001060315	A2	20010823	WO 2001-CA197	20010219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001035278	A5	20010827	AU 2001-35278	20010219
	US 2002019363	A1	20020214	US 2001-785235	20010220
PRAI	US 2000-183349P	P	20000218		
	WO 2001-CA197	W	20010219		

OS MARPAT 135:175346
AB The present invention relates to a method for the treatment or prevention of Flavivirus infections using nucleoside analogs in a host comprising administering a therapeutically effective amt. of the nucleoside analog or

a pharmaceutically acceptable salt thereof.

IT **70580-87-9 85708-20-9 123402-20-0 123402-25-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for treatment or prevention of flavivirus infections using nucleoside analogs and their combination with other agents in relation to **hepatitis** C virus RNA-dependent RNA polymerase (NS5B protein))

RN 70580-87-9 CAPLUS
CN Cytidine, 3'-azido-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 85708-20-9 CAPLUS
CN Cytidine 5'-(tetrahydrogen triphosphate), 3'-azido-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123402-20-0 CAPLUS
CN Cytidine, 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123402-25-5 CAPLUS
CN Cytidine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2002 ACS
AN 1990:36387 CAPLUS
DN 112:36387
TI Preparation of D-arabino- and ribofuranosylpurine and pyrimidine nucleosides for treatment of retrovirus infections
PA Aktieselskabet Atlas, Swed.
SO Jpn. Kokai Tokkyo Koho, 21 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 01151595	A2	19890614	JP 1988-276363	19881102
	EP 322384	A1	19890628	EP 1988-850370	19881027
	EP 322384	B1	19960313		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 135363	E	19960315	AT 1988-850370	19881027
	DK 8806029	A	19890504	DK 1988-6029	19881028
	AU 8824522	A1	19890504	AU 1988-24522	19881031
	AU 615681	B2	19911010		
PRAI	SE 1987-4298		19871103		

OS MARPAT 112:36387
GI



I II



AB The title nucleosides [I; A = Q, Q1; R1 = OH, NH2; R2 = H, F, Cl, Br, iodo, CF3, Me, Et, Bu, Me2CH, cyclopropyl, CH2OH, CH2SH, CH2OMe, CHMe2OH, CH2SMe, CH:CH2, CH:CHMe, CH:CHCF3, CMe:CH2, CH2CH:CH2, C.tplbond.CH, C.tplbond.CMe, C.tplbond.CCF3, CH2C.tplbond.CH; R3, R4 = H, OH, NH2; R5 = H, O, OMe; R6 = H, F, Cl, Br, iodo, OMe, cyano, C.tplbond.CH, N3; R7 = F, Cl, Br, iodo, OH, OR8, O2CR9, O2CR10, OSO2R10, PO3H; R8 = C1-6 alkyl, (un)substituted arylalkyl; R9 = H, R10; = C1-17 alkyl, (un)substituted arylalkyl or aryl; with various provison that, e.g. (a) when R5 = H, R6 .noteq. H, N3 and (b) when R5 = H, R7 = OH, A = thymine , cytosine, .beta.-adenine or .beta.-guanidine, R6 .noteq. F], more specifically (II; R = Pr; R7 = H) (III) and their pharmacol. acceptable salt are prepd. for the treatment of infection with retrovirus [e.g. human immunodeficiency virus (HIV)] or **hepatitis** B virus in mammals and humans. Thus, MeC(OSiMe3):NSiMe3 was added to a suspension of 5-propyluracil and 3'-fluoro-3'-deoxythymidine in MeCN. After stirring 1 h, CF3SO3SiMe3 was added and the resulting mixt. was stirred 138 h at room temp., evapd. in vacuo, and treated with H2O to give, after filtration and purifn. by HPLC on a C18-column, 7% III. III, II (R = Et, R7 = H), II (R = R7 = H), and II (R = Me, R7 = Ac) in vitro inhibited the HIV infection of H9 cells with IC50 values of 1, <1, 0.5, and <0.01 .mu.M, resp.

IT **99614-77-4P 124493-83-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of, as virucide)

RN 99614-77-4 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-azido-3-deoxy-.beta.-D-arabinofuranosyl)-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 124493-83-0 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-.beta.-D-arabinofuranosyl)-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2002 ACS
AN 1989:526519 CAPLUS
DN 111:126519
TI Inhibition of the replication of human **hepatitis** B virus
AU Tsibinogin, V. V.; Kraevskii, A. A.; Bibilashvili, R. Sh.; Grens, E.; Kiselev, L. L.
CS Inst. Org. Synth., Riga, 226006, USSR
SO Molekulyarnaya Biologiya (Moscow) (1989), 23(4), 983-7
CODEN: MOBIBO; ISSN: 0026-8984
DT Journal
LA Russian
AB Several nucleoside 5'-triphosphate analogs were investigated as inhibitors of human **hepatitis** B virus replication. Different analogs inhibited DNA synthesis differently, 3'-azido-2',3'-dideoxythymidine 5'-triphosphate being the most active compd. This inhibitor blocked DNA synthesis by 50% at an inhibitor:substrate molar ratio of 1:8, and by 80% at 1:1. The hypothesis is formulated that 3'-azido-2',3'-deoxythymidine 5'-triphosphate inhibits RNA-directed viral DNA replication due to incorporation of this compd. into the 3'-termini of newly synthesized DNA chains.
IT **99614-92-3**
RL: BIOL (Biological study)
(**hepatitis** B virus of humans replication inhibition by)
RN 99614-92-3 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-azido-3-deoxy-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-.beta.-D-arabinofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 8 OF 9 USPATFULL
AN 2002:32541 USPATFULL
TI Method for the treatment or prevention of flavivirus infections using nucleoside analogues
IN Ismaili, Hicham Moulay Alaoui, Montreal, CANADA
Cheng, Yun-Xing, Dollard-des-Ormeaux, CANADA
Lavallee, Jean-Francois, Bellefeuille, CANADA
Siddiqui, Arshad, Dollard-des-Ormeaux, CANADA
Storer, Richard, Baie d'Urfe, CANADA
PI US 2002019363 A1 20020214
AI US 2001-785235 A1 20010220 (9)
PRAI US 2000-183349P 20000218 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, PC, 2200 CLARENDON BLVD, SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings

LN.CNT 1165
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method for the treatment or prevention of Flavivirus infections using nucleoside analogues in a host comprising administering a therapeutically effective amount of a compound having the formula I or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **70580-87-9 85708-20-9 123402-20-0**
123402-25-5
(method for treatment or prevention of flavivirus infections using nucleoside analogs and their combination with other agents in relation to hepatitis C virus RNA-dependent RNA polymerase (NS5B protein))
RN 70580-87-9 USPATFULL
CN Cytidine, 3'-azido-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 85708-20-9 USPATFULL
CN Cytidine 5'-(tetrahydrogen triphosphate), 3'-azido-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123402-20-0 USPATFULL
CN Cytidine, 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123402-25-5 USPATFULL

CN Cytidine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 9 OF 9 USPATFULL
AN 96:29544 USPATFULL
TI 1-(3'-fluoro-2',3'-dideoxy-.beta.-D-ribofuranosyl)-5-substituted pyrimidine nucleosides
IN Johansson, Karl N. G., Enhorna, Sweden
Lindborg, BjoG., Avsjo, Sweden
Norinder, Ulf, Sodertalje all of, Sweden
Stening, Goran B., Sodertalje all of, Sweden
PA Medivir AB, Huddinge, Sweden (non-U.S. corporation)
PI US 5506215 19960409
AI US 1994-354769 19941212 (8)
RLI Continuation-in-part of Ser. No. US 1991-802706, filed on 6 Dec 1991, now abandoned which is a continuation of Ser. No. US 1990-518495, filed on 3 May 1990, now abandoned which is a continuation-in-part of Ser. No. US 1988-266402, filed on 2 Nov 1988, now abandoned
PRAI SE 1987-4298 19871103
DT Utility
FS Granted
EXNAM Primary Examiner: Kunz, Gary L.
LREP Birch, Stewart, Kolasch & Birch
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1253
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A 2',3'-deoxy-3'-fluoro-pyrimidine nucleoside having the formula: ##STR1## wherein R.sup.1 is OH or NH.sub.2 ;

R.sup.2 is CF.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, ##STR2## CH.sub.2 OCH.sub.3, CH.sub.2 SCH.sub.3, CH.dbd.CH.sub.2 CH.dbd.CH--CH.sub.3, C.tbd.CH, C.tbd.C--CH.sub.3 or CH.sub.2 --C.tbd.CH;

or a pharmaceutically acceptable salt thereof.

These nucleoside analogs exhibit antiviral activity against HIV.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **99614-77-4P 124493-83-0P 178374-50-0P**
(prepn. of (fluorodideoxy-.beta.-D-ribofuranosyl)pyrimidine nucleosides as antiviral agents against HIV)
RN 99614-77-4 USPATFULL
CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-azido-3-deoxy-.beta.-D-arabinofuranosyl)-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 124493-83-0 USPATFULL
CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-.beta.-D-arabinofuranosyl)-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 178374-50-0 USPATFULL
CN 2,4(1H,3H)-Pyrimidinedione, 3-benzoyl-1-(3-deoxy-3-fluoro-.beta.-D-arabinofuranosyl)-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>